Skip to main content

Table 1 Patient characteristics

From: Relationship between fluctuations in glucose levels measured by continuous glucose monitoring and vascular endothelial dysfunction in type 2 diabetes mellitus

Age (years) 64.8±12.1
Gender (male/female) 32/25
Body mass index (kg/m2) 25.6±4.8
Duration of diabetes (years) 14.0±11.9
Diabetes therapy  
 diet only 9 (15.8)
 sulfonylurea 21 (36.8)
 pioglitazone 11 (19.3)
 metformin 8 (14.0)
 α-glucosidase inhibitor 9 (15.8)
 dipeptidyl peptidase-4 inhibitor 15 (26.3)
 insulin 15 (26.3)
Other treatments  
 Lipid-lowering drugs 32(56.1)
 Antihypertensive drugs 31(54.4)
Current smokers 16 (28.1)
Prevalence cardiovascular disease 11 (19.3)
Systolic blood pressure (mmHg) 134.1±20.9
Diastolic blood pressure (mmHg) 80.3±13.4
LDL-cholesterol (mg/dl) 118.2±35.7
HDL-cholesterol (mg/dl) 51.7±17.2
Triglyceride (mg/dl) 136.2±90.5
HbA1c (%) 9.0±1.6
Glucose  
 Fasting plasma glucose (mg/dl) 161.3±46.5
 Average (mg/dl)a 176.5±47.8
 SD (mg/dl) a 42.3±13.2
 MAGE (mg/dl) a 110.3±33.4
 MPPGE (mg/dl)a 79.9±33.7
 Time at <70 mg/dl (%)a 1.4±3.4
 Time at ≥140 mg/dl (%)a 67.2±28.4
 Time at ≥200 mg/dl (%)a 31.4±29.3
 L_RHI 0.5±0.2
 Baseline pulse amplitude  
Total 8.1±3.5
 Men 8.1±3.1
 Women 8.0±3.9
  1. Data are mean±SD, n, or n (%). a Measured by the continuous glucose monitoring system.
  2. Abbreviations: LDL low-density lipoprotein; HDL high-density lipoprotein; HbA1c hemoglobin A1c; SD standard deviation; MAGE mean amplitude of glycemic excursion; MPPGE mean postprandial glucose excursions; L_RHI the natural logarithmic scaled reactive hyperemia index.